The global fallopian tube cancer market is expected to register a CAGR of 5.2%, during the forecast period, (2018-2023). North America dominates the market, due to high healthcare expenditure in the region.
Increasing Health Care Expenditure
There are several governments’ initiatives in developed nations all over the world to provide insurance to cancer patients, which allow them to opt for expensive surgeries and therapies involved in the treatment. This is owing to the fact that the number of cancer cases is increasing rapidly. According to a survey in 2017, about 609,640 Americans are expected to die of cancer that’s more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. The increasing government intervention by increasing healthcare expenditure, for insuring cancer patients will boost the market growth heavily in the forecast period. Also, the rising awareness about this type of cancer may act as a major driver for this market.
Adverse Side Effects of Treatment and Toxicity of Drugs
Because many targeted drugs are still quite new, it’s hard to say how long you can expect side effects to last. We do know that some of the side effects from standard chemo drugs can last a lifetime, such as when the drug causes long-term damage to the heart, lungs, kidneys, or reproductive organs. These side effects along with the high costs of treatment may hinder many patients to seek proper treatment. This, in turn, will affect the overall growth of this market.
North America to Dominate the Market
North America dominates the global fallopian tube cancer market, owing to high incidence of cancer and its early diagnosis due to availability of advanced technology, and growing popularity of non-invasive radiation therapies for cancer in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high incidence of cancer diseases, less stringent regulatory scenario, and presence of huge population base.
Key Developments in the Market
Major Players: AMGEN INC., ASTRAZENECA, BAYER, BOEHRINGER INGELHEIM GMBH, BRISTOL-MYERS SQUIBB, CELGENE, ELI LILLY AND COMPANY, AND F. HOFFMANN-LA ROCHE AG, amongst others.
Reasons to Purchase this Report
Customization of the Report
This report can be customized to meet your requirements.
This product will be delivered within 2 business days.
Increasing Health Care Expenditure
There are several governments’ initiatives in developed nations all over the world to provide insurance to cancer patients, which allow them to opt for expensive surgeries and therapies involved in the treatment. This is owing to the fact that the number of cancer cases is increasing rapidly. According to a survey in 2017, about 609,640 Americans are expected to die of cancer that’s more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. The increasing government intervention by increasing healthcare expenditure, for insuring cancer patients will boost the market growth heavily in the forecast period. Also, the rising awareness about this type of cancer may act as a major driver for this market.
Adverse Side Effects of Treatment and Toxicity of Drugs
Because many targeted drugs are still quite new, it’s hard to say how long you can expect side effects to last. We do know that some of the side effects from standard chemo drugs can last a lifetime, such as when the drug causes long-term damage to the heart, lungs, kidneys, or reproductive organs. These side effects along with the high costs of treatment may hinder many patients to seek proper treatment. This, in turn, will affect the overall growth of this market.
North America to Dominate the Market
North America dominates the global fallopian tube cancer market, owing to high incidence of cancer and its early diagnosis due to availability of advanced technology, and growing popularity of non-invasive radiation therapies for cancer in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high incidence of cancer diseases, less stringent regulatory scenario, and presence of huge population base.
Key Developments in the Market
- March 2017: The U.S. Food and Drug Administration approved niraparib (ZEJULA) of Tesaro, Inc., a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy
Major Players: AMGEN INC., ASTRAZENECA, BAYER, BOEHRINGER INGELHEIM GMBH, BRISTOL-MYERS SQUIBB, CELGENE, ELI LILLY AND COMPANY, AND F. HOFFMANN-LA ROCHE AG, amongst others.
Reasons to Purchase this Report
- Current and future global fallopian tube cancer market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements.
This product will be delivered within 2 business days.
Table of Contents
1. Introduction
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Astrazeneca
- Bayer
- Boehringer Ingelheim Gmbh
- Bristol-Myers Squibb
- Celgene
- Eli Lilly And Company
- F. Hoffmann-La Roche Ag
Methodology
LOADING...
